Over the past 12 months, 6 insiders at GENELUX Corp filed 25 open-market SEC Form 4 transactions on GNLX: 0 purchases worth $0 and 25 sales worth $277K. Insiders have been net sellers over this period. The most recent filing was on Jul 1, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 1, 26 | John W Smither | SELL | 12.0K | $2.91 | $35K |
| Jun 3, 26 | Ralph SmallingHead of Regulatory | SELL | 192 | $2.93 | $563 |
| Jun 1, 26 | John Thomas | SELL | 10.0K | $2.98 | $30K |
| May 11, 26 | Joseph CappelloChief Technical Officer | SELL | 605 | $2.97 | $2K |
| May 11, 26 | Ralph SmallingHead of Regulatory | SELL | 270 | $2.98 | $804 |
| May 11, 26 | Yong YuChief Scientific Officer | SELL | 605 | $2.97 | $2K |
| May 11, 26 | Thomas ZindrickPresident and CEO | SELL | 2.8K | $2.94 | $8K |
| Mar 25, 26 | Ralph SmallingHead of Regulatory | SELL | 240 | $2.51 | $602 |
| Mar 24, 26 | Joseph CappelloChief Technical Officer | SELL | 906 | $2.42 | $2K |
| Mar 24, 26 | Ralph SmallingHead of Regulatory | SELL | 345 | $2.42 | $835 |
| Mar 24, 26 | Yong YuSVP, Clinical Development | SELL | 906 | $2.42 | $2K |
| Mar 24, 26 | Thomas ZindrickPresident and CEO | SELL | 3.6K | $2.42 | $9K |
| Mar 2, 26 | John ThomasDirector | SELL | 10.0K | $2.90 | $29K |
| Dec 5, 25 | Ralph SmallingHead of Regulatory | SELL | 165 | $4.69 | $774 |
| Dec 1, 25 | John ThomasDirector | SELL | 10.0K | $5.00 | $50K |
| Nov 17, 25 | Joseph CappelloChief Technical Officer | SELL | 973 | $5.37 | $5K |
| Nov 17, 25 | Ralph SmallingHead of Regulatory | SELL | 343 | $5.37 | $2K |
| Nov 17, 25 | Yong YuSVP, Clinical Development | SELL | 973 | $5.37 | $5K |
| Nov 17, 25 | Thomas ZindrickPresident and CEO | SELL | 4.5K | $5.37 | $24K |
| Sep 3, 25 | Ralph SmallingHead of Regulatory | SELL | 580 | $3.36 | $2K |
| Aug 21, 25 | Joseph CappelloChief Technical Officer | SELL | 1.5K | $3.36 | $5K |
| Aug 21, 25 | Ralph SmallingHead of Regulatory | SELL | 1.2K | $3.36 | $4K |
| Aug 21, 25 | Yong YuSVP, Clinical Development | SELL | 3.2K | $3.36 | $11K |
| Aug 21, 25 | Thomas ZindrickPresident and CEO | SELL | 12.7K | $3.33 | $42K |
| May 12, 25 | Joseph CappelloVP, Pharmaceutical Development | SELL | 4.7K | $2.92 | $14K |
| May 12, 25 | Sean RyderGeneral Counsel | SELL | 4.5K | $2.92 | $13K |
| May 12, 25 | Ralph SmallingHead of Regulatory | SELL | 1.3K | $2.92 | $4K |
| May 12, 25 | Yong YuVP, Clinical Trial Operations | SELL | 5.6K | $2.92 | $16K |
| May 12, 25 | Thomas ZindrickPresident and CEO | SELL | 10.8K | $2.92 | $31K |
| Dec 30, 24 | James L TyreeDirector | SELL | 3.5K | $2.46 | $9K |
| Dec 16, 24 | Joseph CappelloVP, Pharmaceutical Development | SELL | 6.3K | $2.34 | $15K |
| Dec 16, 24 | Ralph SmallingHead of Regulatory | SELL | 2.5K | $2.34 | $6K |
| Dec 16, 24 | Lourie S. ZakChief Financial Officer | SELL | 2.1K | $2.34 | $5K |
| Dec 16, 24 | Thomas ZindrickPresident and CEO | SELL | 14.3K | $2.34 | $33K |
| Sep 13, 24 | Aladar SzalayTenPercentOwner | SELL | 33.1K | $2.57 | $85K |
| Sep 12, 24 | Aladar SzalayTenPercentOwner | SELL | 31.8K | $2.73 | $87K |
| Sep 11, 24 | James L TyreeDirector | SELL | 1.7K | $2.60 | $4K |
| Sep 11, 24 | Aladar SzalayTenPercentOwner | SELL | 31.4K | $2.62 | $82K |
| Sep 10, 24 | Aladar SzalayTenPercentOwner | SELL | 20.4K | $2.51 | $51K |
| Sep 9, 24 | Aladar SzalayTenPercentOwner | SELL | 23.4K | $2.70 | $63K |
| Sep 3, 24 | Aladar SzalayTenPercentOwner | SELL | 42.8K | $2.09 | $89K |
| Aug 30, 24 | Aladar SzalayTenPercentOwner | SELL | 142.6K | $2.17 | $309K |
| Aug 29, 24 | Aladar SzalayTenPercentOwner | SELL | 107.0K | $1.98 | $212K |
| Aug 28, 24 | Aladar SzalayTenPercentOwner | SELL | 15.9K | $2.05 | $33K |
| Aug 27, 24 | Aladar SzalayTenPercentOwner | SELL | 51.6K | $2.11 | $109K |
| Aug 23, 24 | Aladar SzalayTenPercentOwner | SELL | 40.0K | $2.29 | $92K |
| Jun 24, 24 | Caroline JewettHead of Quality | SELL | 5.0K | $2.12 | $11K |
| Jun 24, 24 | Sean RyderGeneral Counsel | SELL | 5.5K | $2.12 | $12K |
| Jun 24, 24 | Yong YuVP, Clinical Trial Operations | SELL | 6.8K | $2.12 | $15K |
| May 29, 24 | Mary MirabelliDirector | BUY | 8.0K | - | $0 |
Over the past 12 months, insiders at GENELUX Corp filed 0 open-market purchases worth $0 and 25 sales worth $277K on GNLX, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 1, 26.
6 different insiders at GENELUX Corp filed open-market SEC Form 4 transactions on GNLX over the last 12 months.
InsiderTape plots every GNLX insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every GENELUX Corp insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →